Hendrikus J. Dubbink

Author

Also Known As

Dubbink, Hendrikus, Dubbink, Hendrikus J, Dubbink, Hendrikus J., E. Dubbink, E.J. Dubbink, Erik Jan Dubbink, H J Dubbink, H. Dubbink, H. J. Dubbink, H.J. Dubbink

220

Publications

7.6K

Citations

H-Index

109

Concepts

All Affiliations

Erasmus MC Erasmus MC Cancer Institute Erasmus University Rotterdam Radboud University Nijmegen The Netherlands Cancer Institute

About

Hendrikus J. Dubbink is an author at Erasmus MC specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	37	3.2K
2	Health Sciences	8	8	960
3	Natural Sciences	7	7	436
4	Engineering	2	2	78
5	Public Health	2	2	51

Hendrikus J. Dubbink

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, The Lancet Oncology Neuro-oncologyOncologySingle-agent BevacizumabMetronomic TherapyClinical Trials	2014	738
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge, The Lancet Catnon TrialTreatment StrategiesRadiation TherapyGliomaMedicine	2017	392
<i>IDH1</i> and <i>IDH2</i> Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Clinical Cancer Research	2010	380
The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis Maarten M.J. Wijnenga, Pim J. French, Hendrikus J. Dubbink, Neuro-Oncology	2017	319
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick, The Lancet Oncology Surgical OncologyHealth SciencesGliomaMedicineSecond Interim Analysis	2021	307
Federated learning enables big data for rare cancer boundary detection Sarthak Pati, Ujjwal Baid, Brandon Edwards, Nature Communications	2022	306
<i>MGMT</i> Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951 Martin J. van den Bent, Hendrikus J. Dubbink, Marc Sanson, Journal of Clinical Oncology	2009	253
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria C. Mircea S. Tesileanu, Linda Dirven, Maarten M.J. Wijnenga, Neuro-Oncology	2019	207
The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study Martinus P G Broen, Marion Smits, Maarten M.J. Wijnenga, Neuro-Oncology	2018	195
<i>IDH1</i> mutations in low-grade astrocytomas predict survival but not response to temozolomide Hendrikus J. Dubbink, Walter Taal, Ronald van Marion, Neurology	2009	187

Page 1